Joana Pereira-Sousa

Dr. Joana Pereira-Sousa

ICVS/3B’s - PT Government Associate Laboratory, Braga/Guimarães, Portugal
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Molecular Biology of the Cell
Verified
Journal Article
Open access
FCFung-Yi Chan
Fung-Yi Chan
ASAna M. Silva
Ana M. Silva
JSJoana Saramago
Joana Saramago
Joana Pereira-SousaJoana Pereira-Sousa
Joana Pereira-Sousa
HBHailey E. Brighton
Hailey E. Brighton
ACAna Carvalho
Ana Carvalho
Cytokinesis completes cell division by constriction of an acto-myosin contractile ring that separates the two daughter cells. Here, we use the early C. elegans embryo to explore how the actin filament network in the ring and the surrounding cortex is regulated by the single cytokinesis formin CYK-1 and the ARP2/3 complex, which nucleate non-branched and branched filaments, respectively. We show that CYK-1 and the ARP2/3 complex are the predominant F-actin nucleators responsible for generating distinct cortical F-actin architectures, and that depletion of either nucleator affects the kinetics of cytokinesis. CYK-1 is critical for normal F-actin levels in the contractile ring, and acute inhibition of CYK-1 after furrow ingression slows ring constriction rate, suggesting that CYK-1 activity is required throughout ring constriction. Surprisingly, although the ARP2/3 complex does not localize in the contractile ring, depletion of the ARP2 subunit or treatment with ARP2/3 complex inhibitor delays contractile ring formation and constriction. We present evidence that the delays are due to an excess in formin-nucleated cortical F-actin, suggesting that the ARP2/3 complex negatively regulates CYK-1 activity. We conclude that the kinetics of cytokinesis are modulated by interplay between the two major actin filament nucleators. Video S1: Supplemental Video 1 - CYK-1 and the ARP2/3 complex distinctly contribute to defining the cortical actin filament network during cytokinesis in C. elegans 1-cell embryos. Related to Figure 1B. Spinning disk confocal time-lapse video of the central plane (left) and cell cortex (right) of control (top row), CYK-1 partially depleted (middle row) and ARX-2 depleted (bottom row) 1-cell embryos expressing LifeAct::GFP. Cortical images are maximum intensity projections of seven z-sections 0.5 μm apart taken every 10 seconds from anaphase onset (0:00). Frame rate 5 fps, time stamp min:sec. Scale bar, 10 μm. Download Original Video (3.8 MB) https://ascb-prod-streaming.literatumonline.com/journals/content/mboc/0/mboc.ahead-of-print/mbc.e18-07-0471/20181105/media/mc-e18-07-0471-s07.,1200,900,600,300,150,.mp4.m3u8?b92b4ad1b4f274c70877518410abb28bf45a6fadfff54c0884ea58110075615c1d5919ea753725730a4097154a8f56c8491b2e70b0e87b5e9f35b4d61387d2130c8df350edbabb355e8ef985f87fe75bc1a2492f8c9525d0fea87e376fb9d6cf73f9ffd9f77f3669f3901a8a688da065d049979ccc12c3a9e8a79b5dbddb79ddd1f31762a5ec52b5c8691d652bac309a79e012f0ca1ea6471afe10ee2dc099a8b3ee6478ff42751048733c120fcb Video S2: Supplemental Video 2 - Both ARX-2 and CYK-1 depletions delay cytokinesis. Related to Figures 2B', 2C, 3A and 3B. Spinning disk confocal time-lapse video of a section through the central plane of control (left), ARX-2 depleted (middle) and CYK-1 partially depleted (right) 1-cell embryos undergoing cytokinesis. Embryos express myosinNMY-2::GFP. Time 0:00 corresponds to anaphase onset and frames are 10 seconds apart. Frame rate 5 fps, time stamp min:sec. Scale bar, 10 μm. Download Original Video (5.3 MB) https://ascb-prod-streaming.literatumonline.com/journals/content/mboc/0/mboc.ahead-of-print/mbc.e18-07-0471/20181105/media/mc-e18-07-0471-s08.,1200,900,600,300,150,.mp4.m3u8?b92b4ad1b4f274c70877518410abb28bf45a6fadfff54c0884ea58110075615c1d5919ea753725730a4097154a8f56c8491b2e70b0e87b5e9f35b4d61387d2130c8df350edbabb355e8ef985f87fe75bc1a2492f8c9525d0fea87e376fb9d6cf73f9ffd9f77f3669f3901a8a688da065d049979ccc12c3a9e7a79b5dbddb79dde12eca5ab1396eed27e6d16a298c327cfcf7ea68db83b944fede2e6822a25b8b1fe873786574f4e22a1d21cf3b13 Video S3: Supplemental Video 3 - ARX-2 depletion increases and CYK-1 partial depletion decreases actin levels at the furrow tip. Related to Figures 2G and 5B. Spinning disk confocal time-lapse video of the central plane of control (left), ARX-2 depleted (middle) and CYK-1 partially depleted (right) 1-cell embryos expressing LifeAct::GFP. Time 0:00 corresponds to first frame after shallow deformation and frames are 10 seconds apart. Frame rate 5 fps, time stamp min:sec. Scale bar, 10 μm. Download Original Video (2.0 MB) https://ascb-prod-streaming.literatumonline.com/journals/content/mboc/0/mboc.ahead-of-print/mbc.e18-07-0471/20181105/media/mc-e18-07-0471-s09.,1200,900,600,300,150,.mp4.m3u8?b92b4ad1b4f274c70877518410abb28bf45a6fadfff54c0884ea58110075615c1d5919ea753725730a4097154a8f56c8491b2e70b0e87b5e9f35b4d61387d2130c8df350edbabb355e8ef985f87fe75bc1a2492f8c9525d0fea87e376fb9d6cf73f9ffd9f77f3669f3901a8a688da065d049979ccc12c3a9e6a79b5dbddb79ddacb29abaa6b459c48e8ae23adb429485645500abfbb0656593aac88a3cbf42333397068fdef10102a8e82565eb3e Video S4: Supplemental Video 4 - ARX-2 depletion leads to increased CYK-1::GFP levels on the cortex. Related to Figure 5C-E. Spinning disk confocal time-lapse video of central plane (left) and cell cortex (right) of control (top row) and ARX-2 depleted (bottom row) 1-cell embryos expressing forminCYK-1::GFP. Cortical images are maximum intensity projections of seven z-sections 0.5 μm apart taken every 5 seconds from anaphase onset (0:00). Frame rate 5 fps, time stamp min:sec. Scale bar, 10 μm. Download Original Video (3.3 MB) https://ascb-prod-streaming.literatumonline.com/journals/content/mboc/0/mboc.ahead-of-print/mbc.e18-07-0471/20181105/media/mc-e18-07-0471-s10.,300,150,.mp4.m3u8?b92b4ad1b4f274c70877518515abb28bda92fbabe7b929571bd415190bf44d1790b7324fb90f184f91fab10e395327a1bef9725d0c99a358bbbe69c082a95f9d49957eb2932b2be9a6f328f5ec39bba0a6ae7a27eeec1a23585a926eef68ca717ba2a9ac0a9b2900526d2307439ac38aea8b5ea1f44a6351ec8d932eb190d8d21abc497c0f2922e0c525a80a0337b828b9e14430f8fcc4a1c02c126b6c698c9f72

1 October 2021 in Cytotherapy
Verified
Journal Article
Closed access
CMCláudia R. Marques
Cláudia R. Marques
Joana Pereira-SousaJoana Pereira-Sousa
Joana Pereira-Sousa
Fábio G. TeixeiraFábio G. Teixeira
Fábio G. Teixeira
RSRui A. Sousa
Rui A. Sousa
ATAndreia Teixeira-Castro
Andreia Teixeira-Castro
António SalgadoAntónio Salgado
António Salgado

1 March 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SDSara Duarte-Silva
Sara Duarte-Silva
JSJorge Diogo Da Silva
Jorge Diogo Da Silva
DMDaniela Monteiro-Fernandes
Daniela Monteiro-Fernandes
MCMarta Costa
Marta Costa
ANAndreia Neves-Carvalho
Andreia Neves-Carvalho
Patrícia MacielPatrícia Maciel
Patrícia Maciel
Spinocerebellar ataxia type 3 (SCA3) is an adult-onset neurodegenerative disease caused by a polyglutamine expansion in the ataxin-3 (ATXN3) gene. No effective treatment is available for this disorder, other than symptom-directed approaches. Bile acids have shown therapeutic efficacy in neurodegenerative disease models. Here, we pinpointed tauroursodeoxycholic acid (TUDCA) as an efficient therapeutic, improving the motor and neuropathological phenotype of SCA3 nematode and mouse models. Surprisingly, transcriptomic and functional in vivo data showed that TUDCA acts in neuronal tissue through the glucocorticoid receptor (GR), but independently of its canonical receptor, the farnesoid X receptor (FXR). TUDCA was predicted to bind to the GR, in a similar fashion to corticosteroid molecules. GR levels were decreased in disease-affected brain regions, likely due to increased protein degradation as a consequence of ATXN3 dysfunction being restored by TUDCA treatment. Analysis of a SCA3 clinical cohort showed intriguing correlations between the peripheral expression of GR and the predicted age at disease onset in presymptomatic subjects and FKBP5 expression with disease progression, suggesting this pathway as a potential source of biomarkers for future study. We have established a novel in vivo mechanism for the neuroprotective effects of TUDCA in SCA3 and propose this readily available drug for clinical trials in SCA3 patients.

1 May 2021 in Neurobiology of Disease
Verified
Journal Article
Open access
Joana Pereira-SousaJoana Pereira-Sousa
Joana Pereira-Sousa
BFBruna Ferreira-Lomba
Bruna Ferreira-Lomba
ABAina Bellver-Sanchis
Aina Bellver-Sanchis
DVDaniela Vilasboas-Campos
Daniela Vilasboas-Campos
JFJorge H. Fernandes
Jorge H. Fernandes
Andreia Teixeira-CastroAndreia Teixeira-Castro
Andreia Teixeira-Castro
Machado-Joseph disease (MJD) or Spinocerebellar ataxia type 3 (SCA3) is a progressive neurodegenerative disorder that affects movement coordination leading to a premature death. Despite several efforts, no disease-modifying treatment is yet available for this disease. Previous studies pinpointed the modulation of serotonergic signaling, through pharmacological inhibition of the serotonin transporter SERT, as a promising therapeutic approach for MJD/SCA3. Here, we describe the 5-HT1A receptor as a novel therapeutic target in MJD, using a C. elegans model of ATXN3 proteotoxicity. Chronic and acute administration of befiradol (also known as NLX-112), a highly specific 5-HT1A agonist, rescued motor function and suppressed mutant ATXN3 aggregation. This action required the 5-HT1A receptor orthologue in the nematode, SER-4. Tandospirone, a clinically tested 5-HT1A receptor partial agonist, showed a limited impact on animals' motor dysfunction on acute administration and a broader receptor activation profile upon chronic treatment, its effect depending on 5-HT1A but also on the 5-HT6/SER-5 and 5-HT7/SER-7 receptors. Our results support high potency and specificity of befiradol for activation of 5-HT1A/SER-4 receptors and highlight the contribution of the auto- and hetero-receptor function to the therapeutic outcome in this MJD model. Our study deepens the understanding of serotonergic signaling modulation in the suppression of ATXN3 proteotoxicity and suggests that a potent and selective 5-HT1A receptor agonist such as befiradol could constitute a promising therapeutic agent for MJD.

3 February 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
AJAna Jalles
Ana Jalles
CVCármen Vieira
Cármen Vieira
Joana Pereira-SousaJoana Pereira-Sousa
Joana Pereira-Sousa
DVDaniela Vilasboas-Campos
Daniela Vilasboas-Campos
AMAna Francisca Mota
Ana Francisca Mota
Andreia Teixeira-CastroAndreia Teixeira-Castro
Andreia Teixeira-Castro
The atypical antipsychotic aripiprazole is a Food and Drug Administration-approved drug for the treatment of psychotic, mood, and other psychiatric disorders. Previous drug discovery efforts pinpointed aripiprazole as an effective suppressor of Machado–Joseph disease (MJD) pathogenesis, as its administration resulted in a reduced abundance and aggregation of mutant Ataxin-3 (ATXN3) proteins. Dopamine partial agonism and functional selectivity have been proposed as the main pharmacological mechanism of action of aripiprazole in the treatment of psychosis; however, this mechanism remains to be determined in the context of MJD. Here, we focus on confirming the efficacy of aripiprazole to reduce motor dysfunction in vivo, using a Caenorhabditis elegans (C. elegans) model of MJD, and on unveiling the drug targets required for its positive action against mutant ATXN3 pathogenesis. We employed pharmacogenetics and pharmacological approaches to identify which dopamine and serotonin receptors are critical for aripiprazole-mediated improvements in motor function. We demonstrated that dopamine D2-like and serotonin 5-HT1A and 5-HT2A receptors play important roles in this process. Our findings strengthen the relevance of dopaminergic and serotoninergic signaling modulation against mutant ATXN3-mediated pathogenesis. The identification of aripiprazole’s cellular targets, relevant for MJD and perhaps other neurodegenerative diseases, may pave the way for prospective drug discovery and development campaigns aiming to improve the features of this prototypical compound and reduce side effects not negligible in the case of aripiprazole.

22 April 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
CMCláudia Raquel Marques
Cláudia Raquel Marques
MFMiguel de Almeida Fuzeta
Miguel de Almeida Fuzeta
RCRaquel Medina dos Santos Cunha
Raquel Medina dos Santos Cunha
Joana Pereira-SousaJoana Pereira-Sousa
Joana Pereira-Sousa
DSDeolinda Silva
Deolinda Silva
António SalgadoAntónio Salgado
António Salgado
Parkinson’s disease (PD) is the second most common neurodegenerative disorder and is characterized by the degeneration of the dopamine (DA) neurons in the substantia nigra pars compacta, leading to a loss of DA in the basal ganglia. The presence of aggregates of alpha-synuclein (α-synuclein) is seen as the main contributor to the pathogenesis and progression of PD. Evidence suggests that the secretome of mesenchymal stromal cells (MSC) could be a potential cell-free therapy for PD. However, to accelerate the integration of this therapy in the clinical setting, there is still the need to develop a protocol for the large-scale production of secretome under good manufacturing practices (GMP) guidelines. Bioreactors have the capacity to produce large quantities of secretomes in a scalable manner, surpassing the limitations of planar static culture systems. However, few studies focused on the influence of the culture system used to expand MSC, on the secretome composition. In this work, we studied the capacity of the secretome produced by bone marrow-derived mesenchymal stromal cells (BMSC) expanded in a spinner flask (SP) and in a Vertical-Wheel™ bioreactor (VWBR) system, to induce neurodifferentiation of human neural progenitor cells (hNPCs) and to prevent dopaminergic neuron degeneration caused by the overexpression of α-synuclein in one Caenorhabditis elegans model of PD. Results showed that secretomes from both systems were able to induce neurodifferentiation, though the secretome produced in the SP system had a greater effect. Additionally, in the conditions of our study, only the secretome produced in SP had a neuroprotective potential. Lastly, the secretomes had different profiles regarding the presence and/or specific intensity of different molecules, namely, interleukin (IL)-6, IL-4, matrix metalloproteinase-2 (MMP2), and 3 (MMP3), tumor necrosis factor-beta (TNF-β), osteopontin, nerve growth factor beta (NGFβ), granulocyte colony-stimulating factor (GCSF), heparin-binding (HB) epithelial growth factor (EGF)-like growth factor (HB-EGF), and IL-13. Overall, our results suggest that the culture conditions might have influenced the secretory profiles of cultured cells and, consequently, the observed effects. Additional studies should further explore the effects that different culture systems have on the secretome potential of PD.